Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorSeung-Jung Park
About this trial
The objective of this study is to evaluate effectiveness and safety of the new drug-eluting stent (DES), as compared with the first-,second-,third-, and fourth-generation DES, in the "real world" daily practice.
Eligibility criteria
Qualifiers
coronary disease amenable to percutaneous coronary intervention (PCI)
no clinical and lesion limitations
Disqualifiers
patients with a mixture of several DES
terminal illness with life expectancy less than 1 year
patients with cardiogenic shock
Trial design
Treatments tested in this trial
- Not listed
Trial groups
50,000 Participants
are grouped into 27 trial groups27
Trial groupsSee each trial group below.
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Korean centresRecruiting Multiple LocationsSouth Korea
Sponsors and collaborators
Seung-Jung Park
Lead sponsor
CardioVascular Research Foundation, Korea
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator
Source ClinicalTrials.gov